a possible increase in acute pancreatitis risk with gliptins (Januvia, etc) and GLP-1 agonists (Byetta, etc)
April 2013
You'll hear more about a possible increase in acute pancreatitis risk with gliptins (Januvia, etc) and GLP-1 agonists (Byetta, etc).
New evidence suggests about one more case of acute pancreatitis for every 50 diabetes patients using these drugs for up to 2 years.
These incretin mimetics and enhancers might cause inflammation that could lead to acute pancreatitis...and possibly pancreatic cancer.
Get concise advice on drug therapy, plus unlimited access to CE
Pharmacist's Letter Canada includes:
- 12 issues every year, with brief articles about new meds and hot topics
- 200+ CE courses, including the popular CE-in-the-Letter
- Quick reference drug comparison charts
- Access to the entire archive